GSK Buys Experimental Multiple Myeloma Drug from Chimagen
GSK will buy a Chimagen trispecific T-cell engager for multiple myeloma. Phase I trials start in 2027. The deal is worth up to $750 million.
/ 491 items
#XY Event-Driven Stocks↓
BioVie Shares Fall After Mixed Phase 2 Long COVID Results for Bezisterim
Phase 2 ADDRESS-LC missed statistical significance overall. 21 of 22 measures favored bezisterim; benefits were strongest in severe-symptom subgroups.
H.C. Wainwright Upgrades Cardiff Oncology After Nerviano Settlement Clears Onvansertib Path
The catalyst: an out-of-court deal that keeps exclusive rights to onvansertib. Cash remains tight.
Vera’s Trutakna Slows Kidney Decline in Two-Year IgAN Trial
Vera’s Trutakna kept kidney function nearly stable over two years in IgAN, cut serious progression risk, and will support a full FDA filing.
Veracyte Buys Convergent Genomics for Up to $180 Million, Adding a Urine Test for Bladder Cancer
Veracyte acquired Convergent Genomics for $150M cash plus up to $30M in milestones, adding UroAmp, a urine tumor DNA test for bladder cancer.
Sionna Moves SION-451 + SION-2222 Into Phase 2a After August Setback
Sionna will start a Q1 2027 Phase 2a trial of SION-451 plus SION-2222 after a missed Trikafta add-on study. A 46% staff cut extends cash into 2H 2029.